CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 50 enrolled
Drug / intervention
SightGlass Vision DOT Spectacle Lensesdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04126057
NCT04126057N/ACompleted
CompareCT.gov

Myopia Assessment of Two Manufacturing Processes for Myopia Management Lenses (MAPLE)

SightGlass Vision, Inc.·interventional·Posted Oct 14, 2019·Updated Jan 25, 2022

In Brief

A clinical study evaluating SightGlass Vision DOT Spectacle Lenses for Juvenile Myopia. Completed, enrolled 50 participants across 5 sites.

Detailed Summary

Randomized, controlled, multisite, subject- and observer-masked, contralateral clinical trial of 6-month duration to compare two SightGlass Vision Diffusion Optics Technology (DOT) spectacle lens manufacturing processes in reducing the progression of juvenile myopia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsJuvenile Myopia
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedOct 14, 2019
Enrollment StartDec 2, 2019
Primary CompletionSep 15, 2020
Study CompletionSep 16, 2020
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 6.7 years ago

Interventions

SightGlass Vision DOT Spectacle Lensesdevice

Subjects randomized to test vs control, left eyes and right eyes